Sign in
CompletedNo phase

Safety and Effectiveness of CARE1.02 Spectacle Lens in Myopia Control

Key facts

Who runs it
Zhongshan Ophthalmic Center, Sun Yat-sen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
796 people enrolled
Started
25 Apr 2023
Ended
12 Jun 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • CARE1.02
  • Single-vision spectacle lens
Record updated
12 March 2026

Who can take part

Age
12 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Aged 12 to 17 years
  • Under the condition of bilateral cycloplegic autorefraction, the spherical refractive error of -0.50 to -8.00 D in each eye and astigmatism of not more than 1.50 D and anisometropia of not more than 1.50 D
  • Best-corrected visual acuity of equal or better than 0.00 LogMAR (>= 1.0 as Snellen)
  • The intraocular pressure of 10 to 21mmHg
  • Volunteer to participate in this clinical trial with signature of the informed consent form

Who cannot take part

  • Participation of the drug clinical trial within three month and the device clinical trial within one month
  • Participation of any myopia control clinical research trial within three months, and currently using rigid contact lenses (including nursing products), multifocal contact lenses, progressive multifocal lenses and other specially designed myopia control lenses, atropine drugs, etc
  • History of eye injury or intraocular surgery
  • Ocular disease, such as uveitis and other inflammatory diseases,glaucoma, cataract, fundus diseases, eye tumors, dominant strabismus, and any eye diseases that affect visual function
  • Systemic diseases causing low immunity (such as diabetes, Down's syndrome, rheumatoid arthritis, psychotic patients or other diseases that researchers think are not suitable for wearing glasses)
  • Clinically abnormal slit-lamp findings
  • Abnormal fundus examination
  • Only one eye meets the inclusion criteria
  • Unable to have regular follow-up

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

China is a major country in myopia, with the highest number of teenagers suffering from myopia. Controlling the progression of myopia and the related complications caused by axial elongation have clinical significance and social value. Currently. There is a lack of researches on the impact of specially designed myopia control spectacle lens in adolescents aged 12 and above. Therefore, The researchers plan to conduct a randomized controlled trial among myopia adolescents aged 12-17 in middle and high schools in Guangzhou, to test and verify the safety and effectiveness of CARE1.02 on myopia control compared with single-vision spectacle lens.

The 2 groups in the trial

  • Intervention groupTreatment being tested

    CARE1.02

    Treatment: CARE1.02

  • Control groupExisting treatment, for comparison

    Single-vision spectacle lens

    Treatment: Single-vision spectacle lens

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Effectiveness of CARE1.02 Spectacle Lens Versus Single-vision Spectacle Lens in Myopia Control: a Randomised Controlled Trial
Record updated
12 March 2026